title: [Pure lower motoneurone syndrome in a series of six patients].
abstract: BACKGROUND
  Lower motoneurone syndromes (SMNI) have been defined by their clinical pattern, anomalies in nerve conduction and the presence of antiglycolipid antibodies. The possible response to immunotherapy is another characteristic which makes these syndromes interesting.
  
  
  METHODS
  We studied the clinical and electrophysiological data, clinical progress and response to treatment of a series of six patients, with a pure lower motoneurone syndrome, with a follow up period of between 5 and 13 years.
  
  
  CONCLUSIONS
  The clinical phenotype of our patients was: male, middle aged, the clinical topography showed only lower motoneurone involvement, predominantly or exclusively limited to the upper limbs, asymmetrical, distal rather than proximal, with a chronic course progressing initially but later becoming stable. From the electrophysiological point of view some of our cases were of SMNI. In these the conduction block was not permanent although there were signs of axon loss and multifocal demyelination. Response to treatment with intravenous immunoglobulins was seen in patients with anti GMI antibodies of IgM type and recent signs of clinical deterioration, whether there were conduction blocks present or not. In the cases which responded to this treatment there was tolerance and dependence following repeated transfusions of IV IgG.
authors: Servicio de Neurología, Hospital Clínico Universitario de Zaragoza, Zragoza, España. plarrode@nacom.es
authors: P
authors: P
authors: Larrodé
authors: C
authors: C
authors: Iñiguez Mart nez
authors: S
authors: S
authors: Santos
authors: S
authors: S
authors: Adelantado
authors: P
authors: P
authors: González
authors: F
authors: F
authors: Morales
mesh_terms: D000328:Adult; D000906:Antibodies / Q000276:immunology; D002908:Chronic Disease; D016537:Gangliosidosis, GM1 / Q000276:immunology; D006017:Glycolipids / Q000276:immunology; D006801:Humans; D016756:Immunoglobulins, Intravenous / Q000627:therapeutic use*; D008297:Male; D008475:Median Nerve / Q000503:physiopathology; D008875:Middle Aged; D016472:Motor Neuron Disease / Q000188:drug therapy* / Q000276:immunology / Q000503:physiopathology; D009431:Neural Conduction / Q000502:physiology; D010543:Peroneal Nerve / Q000503:physiopathology; D011826:Radial Nerve / Q000503:physiopathology; D013979:Tibial Nerve / Q000503:physiopathology
chemical_list: D000906:Antibodies; D006017:Glycolipids; D016756:Immunoglobulins, Intravenous